Glutamate and its role in psychiatric illness

Human Psychopharmacology

Volumn 16, Issue 2, 2001, Pages 139-146

  Belsham, Brendan ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Bipolar; Depression; Glutamate; NMDA; Receptor; Schizophrenia

Indexed keywords

2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANTIDEPRESSANT AGENT; CALCIUM; CLOZAPINE; CYCLOSERINE; DIZOCILPINE; DOPAMINE; FLUORODEOXYGLUCOSE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; HALOPERIDOL; KAINIC ACID RECEPTOR; KETAMINE; LAMOTRIGINE; MESSENGER RNA; METABOTROPIC RECEPTOR; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; PLACEBO;

AFFECTIVE NEUROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MOVEMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE MARKER; DRUG USE; HEREDITY; HUMAN; LIMBIC SYSTEM; MANIC DEPRESSIVE PSYCHOSIS; MEMORY; MENTAL DISEASE; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PERCEPTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 0035079771     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.279     Document Type: Article

References (65)

1. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phenyclidine
2. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
3. Measles virus-induced hippocampal neurodegeneration in the mouse: A novel, subacute model for testing neuroprotective agents
4. Thalamic abnormalities in schizophrenia visualised through magnetic resonance image averaging
5. Some cytoarchitectural abnormalities in the entorhinal cortex in schizophrenia
6. Deficits in small interneurons in cingulate cortex of schizophrenic and schizoaffective patients
7. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders
8. Supersensitive platelet glutamate receptors as a peripheral marker in schizophrenia
9. A regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging
10. Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus
11. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression
12. The NMDA antagonist MK801 causes marked psychomotor stimulation in monoamine-depleted mice
13. A glutamatergic deficiency model of schizophrenia
14. Differential modulation by dopamine of responses evoked by excitatory amino acids in human cortex
15. Lack of evidence for close linkage of the glutamate GluR6 receptor gene with schizophrenia
16. A 'glutamatergic hypothesis' of schizophrenia: Rationale for pharmacotherapy with glycine
17. Clozapine treatment increases serum glutamate and aspartate compared to conventional antipsychotics
18. Placebo-controlled trial of glycine added to clozapine in schizophrenia
19. Glycine agonists: What can they teach about schizophrenia [comment]?
20. Prenatal ethanol exposure decreases hippocampal 3H-glutamate binding in 45-day-old rats
21. Neuroexcitatory plasma amino acids are elevated in migraine
22. Molecular neurobiology of glutamate receptors
23. D-Cycloserine added to clozapine for patients with schizophrenia
24. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
25. The dopamine hypothesis: An overview of studies with schizophrenic patients
26. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
27. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
28. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
29. NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides
30. Hypobaric ischaemic conditions produce glutamate-like cytopathology in infant rat brain
31. Recent Advances in the phencyclidine model of schizophrenia
32. Plasma glutamate decarboxylase activity in neuropsychiatry
33. The olfactory bulbectomized rat as a model of depression: An update
34. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem
35. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
36. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes
37. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy
38. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
39. Subanaesthetic doses of ketamine stimulate psychosis in schizophrenia
40. Excitatory amino acids as a final common pathway for neurologic disorders
41. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistent depression: Modulation by treatment with antidepressants and prediction of clinical responsivity
42. Physiological antagonism between 5-hydroxytryptamine (2A) and group II metabotropic glutamate receptors in prefrontal cortex
43. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment
44. Neurotoxicity of N-methyl-D-aspartate is markedly enhanced in developing rat central nervous system
45. Adult schizophrenia following prenatal exposure to an influenza epidemic
46. Activation of glutamatergic transmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
47. Piracetam in the treatment of schizophrenia: Implications for the glutamate hypothesis of schizophrenia
48. Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment
49. Glutamate receptor dysfunction and schizophrenia
50. Effect of clozapine and adjunctive high dose glycine in treatment-resistant schizophrenia
51. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label, pilot study
52. Activation of dopamine receptors inhibits calcium-dependent glutamate release from corticostriatal terminal in vitro
53. The role of 5-HT2A receptors in antipsychotic activity
54. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome
55. Excitatory amino acids: Implications for psychiatric disorders research
56. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
57. The glutamatergic basis of human alcoholism
58. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
59. Excitatory amino acid receptors in Schizophrenia
60. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients
61. Glycine therapy of schizophrenia
62. The biological basis of schizophrenia: New directions
63. Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects
64. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls